Based on our results of the impact of DB-ADCC the expression of TIGIT, and of PD-1 on effector cells, especially on NK cells, and their respective ligands on tumor cells, we next addressed the question of whether the blockade of these immune checkpoints leads to a stronger activation of NK cells and, in turn, augments DB-ADCC. The gene discussed is TIGIT; the disease is neoplasm.